Vistagen (NASDAQ: VTGN) cuts 31% of its workforce to preserve capital for fasedienol

Posted by Joseph Casey on Oct 31st, 2026

What happened

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) cut its workforce by approximately 31% on Oct. 26 to reduce operating expenses and preserve capital.

The company said it is keeping the clinical, regulatory, technical and corporate capabilities needed for U.S. registration-directed Phase 3 development of fasedienol, its lead clinical-stage candidate for social anxiety disorder. It also retains capacity for potential future development of two lead Phase 2 candidates, itruvone for major depressive disorder and refisolone for menopausal hot flashes. The reduction is meant to align the size and structure of the workforce with late clinical-stage priorities.

Affected employees may receive cash severance and temporary healthcare coverage if they are eligible, elect it and enter into an effective separation agreement that includes a general release of claims. Vistagen estimates severance and termination costs of approximately $1.0 million.

Key numbers

Metric	Latest	Source
Workforce reduction	approximately 31%	SEC 8-K
Estimated annual salary and benefits savings	approximately $3.2 million	SEC 8-K
Estimated severance and termination costs	approximately $1.0 million	SEC 8-K

Why it matters

Vistagen expects the cut to save approximately $3.2 million a year in salary and benefits. That is more than triple the one-time severance and termination estimate, so the near-term cash effect points toward preservation.

OptimistFi has argued that VTGN is a high-burn, late-stage biotech option whose value depends on clinical and regulatory validation and financing terms far more than on revenue. A smaller payroll helps the financing side of that view, while keeping the Phase 3 team intact protects the clinical side. The two Phase 2 candidates are described only as potential future development, so the cut trades payroll for focus on fasedienol.

The numbers are estimates. The company says it may incur additional costs not currently contemplated and that actual results may differ materially. The cut does not by itself resolve clinical, regulatory or financing risk, which is why OptimistFi reads the filing as mixed for the case.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next quarterly report is the first test. Falling operating expenses and cash usage would support the savings estimate, while added restructuring costs would cut against it.